Welcome, Guest. Please login or register.
July 18, 2024, 05:57:41 am

Login with username, password and session length

  • Total Members: 37801
  • Latest: Tirnum
  • Total Posts: 774095
  • Total Topics: 66453
  • Online Today: 3219
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 0
Guests: 2750
Total: 2750


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Sunlenca Plus Two Antibodies Shows Promise for Twice-Yearly Treatment  (Read 4845 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,688
  • Threads: @jim16309
    • Social Media: Threads
NCT04811040 & next planned phase 2: NCT05729568

Very small (white & male) group but still interesting initial results.

POZ.com article in full: https://www.poz.com/article/sunlenca-plus-broadly-neutralizing-antibodies-shows-promise-twiceyearly-hiv-treatment

In Brief:

Two studies showed that Sunlenca has the potential to be used as a component of a long-acting treatment regimen, but so far there are no other drugs that can be given at such a long interval, so it still must be taken with daily pills. The approved regimen with the longest duration, ViiV Healthcare’s Cabenuva (injectable cabotegravir and rilpivirine), is administered once monthly or every other month.

Combining Sunlenca with long-acting broadly neutralizing antibodies could be another path forward. However, they are prone to resistance as the virus mutates, so they likely will work best in combination regimens.

Eron and colleagues evaluated a regimen of Sunlenca plus two bnAbs administered every six months. This clinical trial (NCT04811040) enrolled people who were on antiretroviral therapy with an undetectable viral load for at least 18 months. The participants were tested to ensure that their HIV was sensitive to both antibodies. Among 124 people initially screened, 55 met the susceptibility criteria. Of these, 34 were not enrolled because of a temporary clinical hold on Sunlenca (due to a problem with the original glass vial) or for other reasons.

Of the remaining 21 people, all but three were men, a majority were white and one third were Latino. The median age was 44 years, and they had been diagnosed with HIV for a median of 8.2 years and on treatment for a median of 2.6 years. All had a current CD4 count above 500, with a median of approximately 900, and they had never fallen below 350.

The study was originally designed to run for 52 weeks, at which point participants would restart their prior antiretroviral regimen. However, when Sunlenca became unavailable due to the clinical hold, the study was halted at 26 weeks, after just one dose, Eron explained.

Sunlenca, teropavimab and zinlirvimab (using either dose) all remained well above therapeutic levels through 26 weeks. At that point, 90% of participants in both groups maintained an undetectable viral load. One person who received the higher dose of zinlirvimab decided he preferred pills and withdrew from the study. One person in the lower-dose group experienced viral rebound, resumed their baseline regimen and again achieved viral suppression. CD4 counts remained stable in both groups.

“This study demonstrates that a combination of the bNAbs teropavimab and zinlirvimab together with lenacapavir can sustain viral suppression for six months in selected people with HIV,” the investigators concluded.

Upcoming phase 2:

Related thread:

https://forums.poz.com/index.php?topic=75017.0: Lenacapavir capsid inhibitor (GS-6207) - CAPELLA trial & CALIBRATE trial
« Last Edit: March 01, 2023, 03:17:40 pm by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram


Terms of Membership for these forums

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.